Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Adaptimmune Therapeutics PLC Director's Dealing 2022

May 5, 2022

34721_dirs_2022-05-04_72579d1d-e5f5-4a05-9410-a6496ace25b5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-05-04

Reporting Person: Brewer Joanna Elizabeth (Chief Scientific Officer)

More from Adaptimmune Therapeutics PLC

Major Shareholding Notification 2026
Feb 17
Regulatory Filings 2025
Nov 17
Major Shareholding Notification 2025
Nov 14
Regulatory Filings 2025
Nov 13
Regulatory Filings 2025
Nov 13
Regulatory Filings 2025
Oct 28
Regulatory Filings 2025
Oct 28
Regulatory Filings 2025
Oct 28
Regulatory Filings 2025
Oct 28
Delisting Announcement 2025
Oct 28
View all filings →